Home > Core technology > Novel Dendritic Cell (DC) Tumor Vaccine Technology
Dendritic cells (DCs) are the most potent professional antigen-presenting cells in vivo, responsible for capturing and processing tumor antigens and presenting them to T lymphocytes, which constitutes a critical step in initiating antigen-specific anti-tumor immune responses.
The company's proprietary DC tumor vaccine is derived from autologous peripheral blood mononuclear cells, which are ex vivo induced to differentiate into DCs. These DCs are then loaded with specific tumor antigens and matured into sensitized DC tumor vaccines, which are reinfused back into the patient. Following reinfusion, the sensitized DCs migrate to lymph nodes and present tumor antigen information to T cells, thereby activating antigen-specific anti-tumor immune responses.